Breaking News

Soligenix Partners with SERB Pharmaceuticals to Supply its Ricin Antigen

SERB Pharmaceuticals pursuing therapeutic treatment against ricin poisoning using Soligenix ricin antigen.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Soligenix, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, has signed a worldwide exclusive license to supply its ricin antigen to SERB Pharmaceuticals for development of a novel therapeutic treatment against ricin toxin poisoning. There is an unmet need for protection against this highly potent toxin for which there is no vaccine or therapeutic intervention available. “We are pleased ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters